Abstract: Interleukin 6 (IL-6) is a multifunctional 21-27kDa glycopeptide with 184 amino acid residues. IL-6 is also responsible for various proinflammatory and anti-inflammatory processes (Agorastos et al., 2014). This study aimed to determine if Interleukin 6 can be used as a biomarker of Ischemic heart disease (IHD). The study employed twenty-four (24) patients and was divided into two groups: IHD patients (n=12) and patients without IHD (n=12). Plasma samples were obtained and IL-6 levels were determined through an Enzyme-Linked Immunosorbent Assay. Results show that there is a significant difference (p<0.001) in the IL-6 levels of IHD patients (median of 33 pg/mL) from patients without IHD (median of 3.8 pg/mL). Based on these findings, those with an increased IL-6 level (> 5 pg/mL) are 25.0 times more likely to have IHD than those without increased IL-6 levels. Furthermore, it was found that for every 1 pg/mL increase in IL-6, the chances of developing the disease increases by 1.24 [CI95%: 1.03 to 1.48]. From these findings, it can be inferred that Interleukin 6 can be used as a biomarker of ischemic heart disease.